NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

CPI-006

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name
CPI-006
DrugBank Accession Number
DB16488
Background

CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy. NCT03454451 focused on advanced cancers (e.g., non-small cell lung cancer, renal cell cancer, colorectal cancer). NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • IMMUNOGLOBULIN G1 (302-GLUTAMINE), ANTI-(HUMAN 5'-NUCLEOTIDASE) (HUMAN-MUS MUSCULUS MONOCLONAL CPI-006 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS-MUSCULUS MONOCLONAL CPI-006 .KAPPA.-CHAIN, DIMER
External IDs
  • CPI-006
  • CPX-006
Unlock the secrets to drugging the undruggable
Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.
Download eBook
Unlock the secrets to drugging the undruggable
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

CPI-006 is a humanized monoclonal antibody which binds to the CD73 cell-surface ectonucleotidase and causes activation of B cells and production of antibodies. It is an immunomodulatory compound currently being investigated against the SARS-CoV-2 virus.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
23ET6940RM
CAS number
2451856-97-4

References

General References
  1. External Link [Link]
  2. External Link [Link]
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
3TerminatedTreatmentCoronavirus Disease 2019 (COVID‑19)1somestatusstop reasonjust information to hide
1CompletedTreatmentBladder Cancer / Cervical Cancer / Colorectal Cancer / Endometrial Cancer / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Non-Hodgkin's Lymphoma (NHL) / Non-Small Cell Lung Cancer (NSCLC) / Ovarian Cancer / Pancreatic Cancer / Renal Cell Carcinoma (RCC) / Sarcomas / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Triple-Negative Breast Cancer1somestatusstop reasonjust information to hide
1CompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at January 21, 2021 01:47 / Updated at July 19, 2024 10:02